- The FDA approves Medtronic's (NYSE:MDT) InterStim smart programmer for the InterStim system, a sacral neuromodulator used to treat overactive bladder, chronic fecal incontinence and non-obstructive urinary retention.
- The company says the smart programmer streamlines multiple devices into a single intuitive touch screen Samsung mobile device, enabling clinicians to customize each patient's care and allowing patients to manage their therapy simply and discreetly.